Background: Breast carcinoma is the most common malignant tumour and the leading cause of carcinoma death in women, with more than 2.1 million cases occurring worldwide annually. Currently, routine clinical management of breast cancer incorporates specific molecular markers; namely ER- estrogen receptor, PR-progesterone receptor, HER2-human epidermal growth factor receptor 2 gene, that have been proven to provide therapeutic, predictive and prognostic value. Hence, the present study is being undertaken to analyze the status of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2/neu) and p53; in all these breast carcinomas in respect to histomorphology and lymph node status. Methods: The study included retrospective and prospective cases from Jan 2021 to Oct 2022. After obtaining the informed consent, the study included all the lumpectomy, simple mastectomy and modified radical mastectomy specimens of clinically diagnosed breast malignancy in female of all age group, submitted to the Department of Pathology, GSVM Medical College Kanpur for histopathological study. The histological and IHC was done as per hospital SOPs. The results were analysed using descriptive statistics and making comparisons among the various groups. Categorical data were summarized as in proportions and percentages (%) while discrete in mean and SD. Results: A total of 100 cases of infiltrating breast carcinoma were included in this study. 56% cases belonged to age group of 41-50 years. ER positivity was observed in 68% [68/100] (Figure 1). PR positivity was observed in 38% of cases [38/100]. Her 2neu positivity was observed in 34% of cases (34/100) and Her 2 neu negative was observed in 66% of cases (66/100). Positive P53 staining i.e. more than 10% cells was observed in 28 of cases (28%) and negative in 72 cases (72%). ER and PR positivity were higher in postmenopausal patients 61.8% and 68.4% respectively. Her 2neu positivity was high in postmenopausal group i.e. 82.4%. P53 expression was also high in postmenopausal patients i.e. 89.2%. Conclusion: The expression of the Immunohistochemical study (p53, ER, PR & HER2/neu markers) is an independent prognostic factor for outcome in Breast cancer patients. The results from this study would be used to help developing diagnostic and treatment strategies that are based on the risk factors of the individual patient.